Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

Rhea-AI Summary

Allogene Therapeutics will report third quarter 2023 financial results on November 2, 2023, followed by a conference call and webcast at 2:00 PM PT/5:00 PM ET.

Positive

• Investors can gain insights into Allogene Therapeutics' financial performance for Q3 2023, potentially influencing stock price.

Negative

• None.

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.

Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.

Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Corporate Affairs & Brand Strategy Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

When will Allogene Therapeutics report its Q3 2023 financial results?

Allogene Therapeutics will report its Q3 2023 financial results on November 2, 2023.

What time is the conference call and webcast?

The conference call and webcast will take place at 2:00 PM PT/5:00 PM ET.

Where can I access the listen-only webcast?

The listen-only webcast will be available on Allogene Therapeutics' website under the Investors tab in the News and Events section.

How long will the replay of the webcast be available?

The replay of the webcast will be available on the Company's website for approximately 30 days.

How can I register for the conference call?

To register for the conference call and have the option to ask a question, please use the provided link.